Amicus Therapeutics (NASDAQ:FOLD) Stock Price Crosses Above 200 Day Moving Average – Time to Sell?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $12.26 and traded as high as $14.46. Amicus Therapeutics shares last traded at $14.46, with a volume of 2,211,441 shares changing hands.

Analyst Ratings Changes

Several analysts have recently issued reports on FOLD shares. TD Cowen cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 target price on the stock. in a research report on Monday, December 22nd. Zacks Research cut shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 26th. Jefferies Financial Group restated a “hold” rating and set a $14.50 target price (down from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, January 22nd. Guggenheim cut shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 5th. Finally, Citigroup restated a “neutral” rating and set a $14.50 target price (down from $17.00) on shares of Amicus Therapeutics in a research report on Monday, December 22nd. Three investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $15.39.

Amicus Therapeutics Trading Up 0.1%

The stock’s fifty day simple moving average is $14.39 and its 200-day simple moving average is $12.30. The firm has a market cap of $4.54 billion, a PE ratio of -180.75 and a beta of 0.48. The company has a debt-to-equity ratio of 1.43, a current ratio of 2.84 and a quick ratio of 1.88.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03). Amicus Therapeutics had a positive return on equity of 4.15% and a negative net margin of 4.27%.The company had revenue of $185.21 million during the quarter, compared to analysts’ expectations of $185.00 million. During the same period in the prior year, the business posted $0.09 EPS. The company’s quarterly revenue was up 23.7% on a year-over-year basis. On average, sell-side analysts forecast that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 75,000 shares of Amicus Therapeutics stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $14.31, for a total value of $1,073,250.00. Following the sale, the chief executive officer owned 1,021,180 shares in the company, valued at $14,613,085.80. This trade represents a 6.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 2.20% of the company’s stock.

Institutional Trading of Amicus Therapeutics

Several institutional investors have recently modified their holdings of FOLD. Goldman Sachs Group Inc. grew its position in shares of Amicus Therapeutics by 7.7% in the first quarter. Goldman Sachs Group Inc. now owns 2,703,577 shares of the biopharmaceutical company’s stock valued at $22,061,000 after purchasing an additional 194,213 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Amicus Therapeutics by 11.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,072,474 shares of the biopharmaceutical company’s stock valued at $8,751,000 after purchasing an additional 113,803 shares during the period. Intech Investment Management LLC grew its position in shares of Amicus Therapeutics by 37.1% in the first quarter. Intech Investment Management LLC now owns 170,922 shares of the biopharmaceutical company’s stock valued at $1,395,000 after purchasing an additional 46,218 shares during the period. Strs Ohio acquired a new stake in shares of Amicus Therapeutics in the first quarter valued at about $30,000. Finally, Cetera Investment Advisers acquired a new stake in shares of Amicus Therapeutics in the second quarter valued at about $79,000.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure?based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.